Synklino Doses First Patient in Phase 1 SYN002 CMV Trial
COPENHAGEN, Denmark — May 28, 2026 Synklino A/S announced that the first patient has been dosed in a first-in-human...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark — May 28, 2026 Synklino A/S announced that the first patient has been dosed in a first-in-human...
IRVINE, Calif., May 20, 2026 Eledon Pharmaceuticals announced that new long-term clinical data from its Phase 2 BESTOW trial...
LUND, Sweden, Sept. 24, 2025 — Hansa Biopharma has announced that imlifidase successfully met its primary endpoint in the...
